Sexual and Gender Minorities Twice as Likely to Experience Cancer-Related Pain For this study, researchers used data from the Behavioral Risk Factor Surveillance System to compare experiences of cancer-related pain among sex and gender minority survivors and heterosexual cisgend...

When it comes to cancer-related pain, sexual and gender minorities are at an increased risk. Gender minority survivors were most likely to report pain, at 27.69% compared with 9.48% in heterosexual cisgender survivors. #OncSky

Study published in @aacrjournals.bsky.social

https://bit.ly/4sXmuTs

Immunosuppressants: What is their role in cancer care? What are immunosuppressants? Jeremy Ramdial, M.D., explains how these drugs work, their role in stem cell transplants, and how they help manage graft vs. host disease.

Sometimes, cancer patients are given immunosuppressants as part of their treatment plan.

Our Dr. Jeremy Ramdial explains what they are, why someone may need them and how they work: spr.ly/63324B6LTa8 #OncSky #EndCancer

Okra water: Should you be drinking it? Is okra water actually good for you? Senior clinical dietician Rachel Murphy weighs in on the science behind the trend, from its alleged blood sugar and weight loss benefits to the potential risks.

Proponents of drinking okra water claim it can help with a variety of systems in your body. But do any of those claims hold up?

Clinical Dietitian Rachel Murphy shares what you should know: spr.ly/63320B6I8RG #OncSky #EndCancer

Researchers find new target to sensitize pancreatic tumors to immunotherapy Researchers find new target to sensitize pancreatic tumors to immunotherapy

What if there was a way to identify which patients with pancreatic cancer were more likely to benefit from immunotherapy?

A group of UT MD Anderson researchers found a biomarker that may be able to do that. Learn more: spr.ly/6012B6x8Lj #OncSky #EndCancer

APEX1 Could Be a Novel Biomarker for CCA and HCC The levels of APEX1 in the serum could be used as a diagnostic biomarker in cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC), research shows.

The levels of apurinic/apyrimidinic endodeoxyribonuclease 1 (#APEX1) in the serum could be used as a diagnostic biomarker in cholangiocarcinoma (#CCA) and hepatocellular carcinoma (#HCC). Study in the Egyptian Liver Journal.

Read more: https://bit.ly/4truf3S

#RareDisease #MedSky #OncSky

Adding RFA to chemotherapy fails to boost survival for locally advanced pancreatic cancer Radiofrequency ablation does not improve overall survival for patients with locally advanced pancreatic cancer who are undergoing chemotherapy and is associated with poorer quality of life.

#MedNews - Radiofrequency ablation does not improve overall survival for patients with locally advanced #PancreaticCancer who are undergoing chemotherapy and is associated with poorer quality of life.

👉 buff.ly/pJPGaeb

#GastroSky #OncSky

Diagnostics in cardio-oncology: a focus on anthracyclines The dose-dependent cardiotoxicities of anthracyclines require careful cardiovascular monitoring. Discover how the latest diagnostic advances in imaging modalities, biomarkers, and genetic screening…

The dose-dependent cardiotoxicities of #anthracyclines require careful cardiovascular monitoring.

Discover how the latest diagnostic advances in imaging modalities, biomarkers, and genetic screening are refining patient care.

👉 buff.ly/Lc4oe22

#CardioSky #OncSky

Patients deserve to feel recognized when they participate in research.

Too often in the past, research has been done TO patients rather than done WITH them.

Read this article @bmkwan.bsky.social worked on with @thelizarmy.bsky.social: buff.ly/43MDfBM

#medsky #cansky #btsm #radonc #oncsky

Metastatic melanoma survivor trusts UT MD Anderson’s expertise and research Joe Eastin faced multiple melanoma recurrences before seeking a second opinion at UT MD Anderson. Here he shares how immunotherapy and a caring team of doctors and researchers helped him through a metastatic melanoma diagnosis.

“I think the science around advanced melanoma treatment is pretty amazing," says Joe Eastin after receiving immunotherapy for metastatic melanoma at UT MD Anderson.

Why he's excited about the future of immunotherapy research: spr.ly/63327B6aDhv #OncSky #EndCancer

#OncologyNurses lead biomarker testing to personalize treatment and mitigate risks. Clinical data integration improves patient outcomes.

Read the review here: ➡️ https://bit.ly/4sXma7d

#MedEd #OncSky #WorldHealthDay #ONASummit

Researchers identify blood-based biomarker for cancer risk in people with Lynch Syndrome Researchers identify blood-based biomarker for cancer risk in people with Lynch Syndrome

Researchers at UT MD Anderson have identified a blood-based biomarker that could help detect cancer risk earlier in people with Lynch syndrome.

Read more: spr.ly/6017B6QjF7 #OncSky #EndCancer

Frontiers | Unravelling prostate cancer risk and protective factors among urology patients in a Tanzanian population BackgroundProstate cancer (PCa) is a leading cause of cancer-related morbidity and mortality among men globally. The prevalence is disproportionate among men...

New: "The intake of red meat was positively associated with the incidence of PCa, whilst the intake of tomatoes, soya and coffee consumption were associated with reduced PCa incidence in our study population." #prostatecancer #cansky #oncology #oncsky #plantbased
www.frontiersin.org/journals/onc...

Blood in semen (hematospermia): Is it a sign of cancer? Blood in semen, also known as hematospermia, usually is not a sign of cancer or anything serious. But it’s also not normal. Urologic oncologist Lisly Chéry, M.D., shares when to see a doctor for blood in your semen and how it’s treated.

There are some infections or inflammatory conditions that can cause you to see blood in your semen, which can be a concerning thing to see.

But Dr. Lisly Chéry shares why it usually isn't something serious: spr.ly/63321B6tmH9 #OncSky #EndCancer

Enhance your knowledge, skills and practice in molecular testing, emerging therapies, and targeted treatments in R/R #AML with this vodcast series hosted by Prof. Amer Zeidan.

All episodes available now 👉 buff.ly/ro4GLtX

#OncSky #HaemSky #MedEd

Shameless plug for my daughter while we watch #NWSL Eat your Arugula boys and girls! youtube.com/shorts/l_7Iu... #cansky #oncsky

SARS-CoV-2 infection heightens the risk of developing HPV-related carcinoma in situ and cancer This study aims to investigate the impact of SARS-CoV-2 infection on HPV-related cancer and carcinoma in situ. We utilized data from TriNetX, a database encompassing 106 healthcare organizations spanning 15 countries and comprising information from ...

starting to see the long-term effects of COVID-19. pmc.ncbi.nlm.nih.gov/articles/PMC... #BlueSky #MedSky #OncSky #SciSky #NurseSky #EMSky

Intralesional IL-2 promising in cutaneous squamous cell carcinoma Intralesional treatment with interleukin-2 therapy elicits a high rate of complete responses in people with cutaneous squamous cell carcinoma.

#MedNews - Intralesional treatment with interleukin-2 therapy elicits a high rate of complete responses in people with cutaneous squamous cell carcinoma.

Full story 👉 buff.ly/Cm9Keyo

#OncSky #SSC

3 reasons appendix cancer is hard to diagnose  Appendix cancer is now known to be distinct from colorectal cancer. But it can still be difficult to diagnose. Why? Gastrointestinal oncologists John Paul Shen, M.D. and Beth Melmink, M.D., weigh in.

Drs. John Paul Shen and Beth Helmink recently shared why appendix cancer can be difficult to diagnose.

Read their insights here: spr.ly/63320B6UtIC #OncSky #Endcancer

It's a tragedy that so many #oncsky and #cansky folks do not know about using gel/ice packs while getting your infusion helps prevent some of the nerve damage / neuropathy. My wife was 4-5 months in before she found out and that's using Scharr in VA and Johns Hopkins. They just fail to mention it

Gotta do what you can. This new chemo (Gem/Tax) is beating her down. #oncsky #cansky

Today, April 3, marks the first-ever #OncologyPharmacistDay! It's the perfect day to acknowledge the two esteemed oncology pharmacists at the UW–Madison School of Pharmacy: Professor Paul Hutson and Associate Professor Lisa Holle (BS ’93, PharmD ’95). #PharmSky #OncSky

Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia Acquired von Willebrand syndrome represents a rare but significant complication of chronic lymphocytic leukemia. This patient achieved remission after treatment with venetoclax plus obinutuzumab.

#MedCase - Acquired von Willebrand syndrome represents a rare but significant complication of chronic lymphocytic #leukemia.

This patient achieved remission after treatment with #venetoclax plus #obinutuzumab.

👉 buff.ly/2QrQ0LE

#OncSky

Stage IV cervical cancer survivor thankful for immunotherapy clinical trial Paulette Burkhart was 70 when she was diagnosed with stage IV cervical cancer. Here she shares why she’s glad she enrolled in an immunotherapy clinical trial at UT MD Anderson and encourages others facing cancer to ask about clinical trials as well.

When Paulette Burkhart was diagnosed with advanced cervical cancer, she met with Dr. Roni Wilke, who told her about an immunotherapy clinical trial.

Two years later, the cancer has had a complete response, and Paulette is doing well: spr.ly/63324B6oFt6 #OncSky #EndCancer

Hormonal management after risk-reducing surgery in BRCA-mutated triple-negative breast cancer survivors Is HRT appropriate after risk-reducing surgery in BRCA mutation carriers with a history of triple-negative breast cancer? What do current international guidelines, evidence, and expert…

Is #HRT appropriate after risk-reducing surgery in BRCA mutation carriers with a history of triple-negative #BreastCancer?

Find out what current international guidelines, evidence, and expert recommendations suggest.

👉 buff.ly/lRxlx9q

#OncSky

Radiation therapy improves outcomes for 'supermassive' bile duct tumors A new study from researchers at The University of Texas MD Anderson Cancer Center demonstrates that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with large bile duct tumors in the liver, known as intrahepatic cholangiocarcinoma.

A new study found that a specialized high-dose type of radiation delivery may significantly improve outcomes for patients with intrahepatic cholangiocarcinoma, when given with standard-of-care chemotherapy.

Learn more: spr.ly/6019B6ovs5 #OncSky #EndCancer

My daughter wants you to eat gooseberries. lol. thanks to all of you who watched her short already. She's helping out in her Mom's (my wife) garden since her Mom is battling Leiomyosarcoma. youtube.com/shorts/tpj8u... #kidsgarden #cansky #oncsky #gardeningtips

"Val-YOU-Based-Care" Episode 1: Dr Kimberly Ku discusses "#tacticalEmpathy" in #oncology. Learn how negotiation techniques from the FBI apply to clinical patient communication.

Read the review and listen to the full episode here: https://bit.ly/4rQ3lS5

#MedEd #OncSky

Researchers from UT MD Anderson developed a first-in-class antibody that targets a protein over expressed in many cancer types, allowing for the creation of a new treatment that brings targeted radiation directly to tumor cells.

Learn more: spr.ly/6013B6o6uJ #OncSky #EndCancer

Lung cancer survivor finds care, support and connection at UT MD Anderson After Daniel West was diagnosed with lung cancer, he chose UT MD Anderson for his treatment.

“We liked that at UT MD Anderson, we were able to talk to all my doctors in the beginning," recalls Daniel West. "Lung cancer is such a serious diagnosis, so I liked that they had a plan for my treatment.”

Read his story: spr.ly/63320B6Wt4k #OncSky #EndCancer

Robot-assisted versus conventional minimally invasive oesophagectomy for oesophageal squamous cell carcinoma (RAMIE): a multicentre, open-label, randomised, phase 3, non-inferiority trial In patients with resectable oesophageal squamous cell carcinoma, robot-assisted oesophagectomy was non-inferior, and seemed superior, to thoracoscopic oesophagectomy in terms of 5-year overall surviva...

🆕 Robot-assisted versus conventional minimally invasive oesophagectomy for oesophageal squamous cell carcinoma (RAMIE): a multicentre, open-label, randomised, phase 3, non-inferiority trial

www.thelancet.com/journals/lan...

#GastroSky #OncSky #SurgSky